Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research

Document Details

Document Type
Pub Defense Publication
Publication Date
Feb 01, 2013
Source ID
10.1016/j.bbmt.2012.11.016

Entities

People

  • Baldeep Wirk
  • César O. Freytes
  • David A. Rizzieri
  • David G. Maloney
  • David I. Marks
  • David J. Inwards
  • Gregory A. Hale
  • Hillard M Lazarus
  • Jack W. Hsu
  • James L. Gajewski
  • Jeanette Carreras
  • Leena V. Maramattom
  • Leona A. Holmberg
  • Linda J. Burns
  • Luciano J. Costa
  • Mehdi Hamadani
  • Michael Lill
  • Mitchell S Cairo
  • Parameswaran N. Hari
  • Richard T. Maziarz
  • Robert Peter Gale
  • Silvia Montoto
  • Thomas G. Gross
  • Timothy S. Fenske
  • William Arcese

Organizations

  • Amgen
  • Blue Cross Blue Shield Association
  • Celgene
  • CellGenix (Germany)
  • Children’s Leukemia Research Association
  • Elevance Health, Inc.
  • GSK
  • Health Resources and Services Administration
  • Kiadis Pharma (Netherlands)
  • Leukemia & Lymphoma Society
  • Medical College of Wisconsin
  • Merck & Co.
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Marrow Donor Program
  • Office of Naval Research
  • Osiris Therapeutics
  • Otsuka (United States)
  • Roche (United States)
  • Sanofi-Aventis
  • Seagen
  • Sigma-Tau Pharmaceuticals (United States)
  • StemCyte
  • Swedish Orphan Biovitrum
  • Tarix Orphan (United States)
  • Terumo BCT (United States)

Tags

Technology Areas

  • Biotechnology